By Lisa Kerner
Charlotte, N.C., June 19 - Amorcyte Inc. said it concluded a $4.2 million round of series A financing.
The proceeds will be used to fund a 40-patient phase 1 clinical trial of cell-based therapies in cardiovascular disease.
Colt Ventures, LLC led the financing round.
Amorcyte is a therapeutics company based in Hackensack, N.J.
| Issuer: | Amorcyte, Inc.
|
| Issue: | Series A financing
|
| Amount: | $4.2 million
|
| Investor: | Colt Ventures, LLC (lead)
|
| Announcement date: | June 19
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
